Kyntra Bio Appoints New Board Member, Announces Leadership Change

SAN FRANCISCO, Oct. 01, 2026 /CourierPR/ -- Kyntra Bio (Nasdaq: KYNB), a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease, today announced the appointment of Andrew E. Singer, MBA to its Board of Directors as an independent director and member of the Audit Committee effective October 1, 2026. The appointment follows the departure of Maykin Ho, Ph.D., who has stepped down from the Board of Directors effective September 30, 2026 after nearly eight years of service.

The appointment of Andrew E. Singer, MBA, brings valuable experience to Kyntra Bio. With more than 25 years of experience spanning investment banking, corporate strategy, business development, and public company leadership, Mr. Singer currently serves as Founder and CEO of Fika Bio Consulting, Inc., a strategic consulting firm. His previous roles include Head of West Coast Biotechnology Investment Banking at Credit Suisse, where he advised biotechnology companies on capital formation, strategic transactions, and corporate development, and Executive Vice President and Chief Financial Officer of Epizyme, where he spent over ten years in the Biotechnology Investment Banking Group. Over the course of his banking career, Mr. Singer advised biotechnology companies on capital formation, strategic transactions, and corporate development, participating in transactions valued in excess of $50 billion. He previously served on the Board of Directors of Enlivex Therapeutics, Ltd. and the J.F. Kapnek Trust.

Kyntra Bio has taken substantial steps to strengthen its financial position and sharpen its focus on its exciting pipeline. The appointment of Andrew E. Singer, MBA, as an independent director and member of the Audit Committee, and the departure of Maykin Ho, Ph.D., are expected to support the company as it advances its programs to create long-term value.

Andrew E. Singer, MBA, is a biotechnology finance and strategy executive with more than 25 years of experience spanning investment banking, corporate strategy, business development, and public company leadership. He currently serves as Founder and CEO of Fika Bio Consulting, Inc., a strategic consulting firm. Prior to Fika Bio Consulting, Mr. Singer served as Head of West Coast Biotechnology Investment Banking at Credit Suisse, where he advised biotechnology companies on capital formation, strategic transactions, and corporate development. He also spent over ten years at RBC Capital Markets in the Biotechnology Investment Banking Group. Mr. Singer previously served on the Board of Directors of Enlivex Therapeutics, Ltd. and the J.F. Kapnek Trust. He holds an MBA with distinction from Harvard Business School and a BA from Yale University.

Kyntra Bio continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker.